ADDEX THERAPEUTICS LTD (MORE TO FOLLOW) Dow Jones Newswires
December 17, 2021 01:00 ET (06:00 GMT)
Addex Raises $10.0 Million in Equity Financing
December 17, 2021 at 01:00 am EST
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.115 CHF | -6.50% |
|
-27.90% | +150.00% |
| Apr. 24 | Top Premarket Decliners | MT |
| Apr. 18 | Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024 |
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Companyâs clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsonâs disease and mGlu3 PAM for neurodegenerative disorders.
Calendar
2024-05-05
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.115
CHF
Average target price
0.16
CHF
Spread / Average Target
+39.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +150.00% | 17.26M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- ADXN Stock
- News Addex Therapeutics Ltd
- Addex Raises $10.0 Million in Equity Financing
